2.50
Hdl Handle:
http://hdl.handle.net/10541/98837
Title:
Hypercalcemia and bone resorption in malignancy.
Authors:
Walls, J; Bundred, Nigel J; Howell, Anthony ( 0000-0002-3879-5991 )
Abstract:
Hypercalcemia is the most common paraneoplastic syndrome associated with cancer. This paper addresses the etiology and pathogenesis of hypercalcemia of malignancy and discusses the relative contributions of local and humoral effects on bone and renal calcium homeostasis. The roles of parathyroid hormone-related protein and other osteolytic cytokines are outlined. New biochemical markers that enable more specific monitoring of the response of bone metastases to treatment are introduced, including urinary excretion of the collagen crosslinks pyridinoline and deoxypyridinoline. The clinical management and prevention of hypercalcemia is systemically outlined, including indications for bisphosphonate, glucocorticoid, and calcitonin therapy. The results of recent trials of bisphosphonate therapy for the prevention of tumor progression and its subsequent problems such as bone pain, fracture, and hypercalcemia also are discussed.
Affiliation:
Department of Surgery, Northern General Hospital, Sheffield, England.
Citation:
Hypercalcemia and bone resorption in malignancy. 1995 (312):51-63 Clin. Orthop. Relat. Res.
Journal:
Clinical Orthopaedics and Related Research
Issue Date:
Mar-1995
URI:
http://hdl.handle.net/10541/98837
PubMed ID:
7634618
Type:
Article
Language:
en
ISSN:
0009-921X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorWalls, Jen
dc.contributor.authorBundred, Nigel Jen
dc.contributor.authorHowell, Anthonyen
dc.date.accessioned2010-05-14T10:02:20Z-
dc.date.available2010-05-14T10:02:20Z-
dc.date.issued1995-03-
dc.identifier.citationHypercalcemia and bone resorption in malignancy. 1995 (312):51-63 Clin. Orthop. Relat. Res.en
dc.identifier.issn0009-921X-
dc.identifier.pmid7634618-
dc.identifier.urihttp://hdl.handle.net/10541/98837-
dc.description.abstractHypercalcemia is the most common paraneoplastic syndrome associated with cancer. This paper addresses the etiology and pathogenesis of hypercalcemia of malignancy and discusses the relative contributions of local and humoral effects on bone and renal calcium homeostasis. The roles of parathyroid hormone-related protein and other osteolytic cytokines are outlined. New biochemical markers that enable more specific monitoring of the response of bone metastases to treatment are introduced, including urinary excretion of the collagen crosslinks pyridinoline and deoxypyridinoline. The clinical management and prevention of hypercalcemia is systemically outlined, including indications for bisphosphonate, glucocorticoid, and calcitonin therapy. The results of recent trials of bisphosphonate therapy for the prevention of tumor progression and its subsequent problems such as bone pain, fracture, and hypercalcemia also are discussed.en
dc.language.isoenen
dc.subjectBone Canceren
dc.subjectBreast Canceren
dc.subject.meshAnimals-
dc.subject.meshBone Neoplasms-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCytokines-
dc.subject.meshDiphosphonates-
dc.subject.meshDisease Progression-
dc.subject.meshHumans-
dc.subject.meshHypercalcemia-
dc.subject.meshOsteolysis-
dc.subject.meshParaneoplastic Syndromes-
dc.titleHypercalcemia and bone resorption in malignancy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, Northern General Hospital, Sheffield, England.en
dc.identifier.journalClinical Orthopaedics and Related Researchen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.